CXCL12 and cancer: Blocking the CXCL12-CXCR4/ACKR3 interaction by administration of small-molecule antagonists or neutralizing antibodies showed to be beneficial in pre-clinical and clinical studies for treatment of cancer, viral infections, IBD, arthritis, asthma, acute lung injury, ALS, and Warts, Hypogammaglobulinemia, Immunodeficiency, and Myelokathexis syndrome (WHIM syndrome).